Avexa Limited - Product Pipeline Review - 2015

Date: November 18, 2015
Pages: 28
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AD85E0E6AFFEN
Leaflet:

Download PDF Leaflet

Avexa Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Avexa Limited - Product Pipeline Review - 2015’, provides an overview of the Avexa Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Avexa Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Avexa Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Avexa Limited’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Avexa Limited’s pipeline products
Reasons to buy
  • Evaluate Avexa Limited’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Avexa Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Avexa Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Avexa Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Avexa Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Avexa Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Avexa Limited Snapshot
Avexa Limited Overview
Key Information
Key Facts
Avexa Limited - Research and Development Overview
Key Therapeutic Areas
Avexa Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Avexa Limited - Pipeline Products Glance
Avexa Limited - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Avexa Limited - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Avexa Limited - Drug Profiles
apricitabine
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit HIV Integrase for HIV / AIDS
Product Description
Mechanism of Action
R&D Progress
AVX-15567
Product Description
Mechanism of Action
R&D Progress
Avexa Limited - Pipeline Analysis
Avexa Limited - Pipeline Products by Target
Avexa Limited - Pipeline Products by Route of Administration
Avexa Limited - Pipeline Products by Molecule Type
Avexa Limited - Pipeline Products by Mechanism of Action
Avexa Limited - Recent Pipeline Updates
Avexa Limited - Dormant Projects
Avexa Limited - Company Statement
Avexa Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Avexa Limited, Key Information
Avexa Limited, Key Facts
Avexa Limited - Pipeline by Indication, 2015
Avexa Limited - Pipeline by Stage of Development, 2015
Avexa Limited - Monotherapy Products in Pipeline, 2015
Avexa Limited - Out-Licensed Products in Pipeline, 2015
Avexa Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015
Avexa Limited - Phase III, 2015
Avexa Limited - Preclinical, 2015
Avexa Limited - Discovery, 2015
Avexa Limited - Pipeline by Target, 2015
Avexa Limited - Pipeline by Route of Administration, 2015
Avexa Limited - Pipeline by Molecule Type, 2015
Avexa Limited - Pipeline Products by Mechanism of Action, 2015
Avexa Limited - Recent Pipeline Updates, 2015
Avexa Limited - Dormant Developmental Projects,2015
Avexa Limited, Subsidiaries

LIST OF FIGURES

Avexa Limited - Pipeline by Stage of Development, 2015
Avexa Limited - Monotherapy Products in Pipeline, 2015
Avexa Limited - Out-Licensed Products in Pipeline, 2015
Avexa Limited - Pipeline by Top 10 Target, 2015
Avexa Limited - Pipeline by Top 10 Molecule Type, 2015
Avexa Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Xention Limited - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 29 pages
Mesoblast Limited - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 51 pages
Pharminox Limited - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 21 pages
Cellmid Limited - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 30 pages

Ask Your Question

Avexa Limited - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: